NCT00217646 - Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2010

Conditions

Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAdult ErythroleukemiaAdult Pure Erythroid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaBlastic Phasede Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome

Interventions

DRUG

Sorafenib Tosylate

Given orally

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH